Abstract:
Provided is a breeding apparatus that can facilitate disposition and collection of a spawning bed. A breeding apparatus (1) includes a breeding area forming member (10) that forms breeding areas (A1, A2) for organisms and is open at least at the bottoms of the breeding areas (A 1, A2), and a spawning bed sheet (41) that forms the bottom surfaces of the breeding areas (A1, A2), has a belt shape, and is provided so as to be movable in a longitudinal direction of the belt shape relative to the breeding area forming member (10).
Abstract:
Provided are a method for targeting a target nucleotide sequence, etc. said method comprising introducing into a cell: (i) CRISPR type I-D Cas proteins Cas5d, Cas6d and Cas7d and a polypeptide containing the N-terminal HD domain of Cas10d, or nucleic acids encoding the proteins and the polypeptide; (ii) a polypeptide that contains not the N-terminal HD domain of Cas10d but the C-terminal partial sequence of Cas10d, or a nucleic acid encoding the polypeptide; and (iii) a crRNA that contains a sequence capable of forming a base pair with the target nucleotide sequence, or a DNA encoding the crRNA.
Abstract:
Provided is a method for simply obtaining a desired size fraction from an aqueous sample containing particles. The method includes the following steps: (1) bringing the aqueous sample containing particles into contact with a superabsorbent polymer to obtain a superabsorbent polymer gel containing a portion of the particles, and (2) mixing the superabsorbent polymer gel with a salt to recover a portion of the particles.
Abstract:
According to a conventional method for treatment of Sandhoff disease and Tay-Sachs disease comprising administering a modified β-subunit to a patient in the form of a protein, it is necessary that administration be performed frequently. This invention relates to a recombinant adeno-associated virus virion comprising: a capsomere comprising a protein capable of forming a virus virion; and a polynucleotide packaged in the capsomere comprising a promoter sequence and nucleotide sequences operably linked to the promoter sequence encoding a first amino acid sequence derived from the amino acid sequence of the β-subunit of wild-type human β-hexosaminidase composed of amino acids 55 to 556 in the sequence as shown in SEQ ID NO: 28 by substitution of amino acids 312 to 318 with glycine, serine, glutamic acid, proline, serine, glycine, and threonine in that order and a second amino acid sequence, which is an amino acid sequence of a signal peptide linked to the N terminus of the first amino acid.
Abstract:
An object of the present invention is to provide a method for producing insulin-producing cells having sufficient glucose responsiveness from mesenchymal stem cells, an insulin-producing cell having sufficient glucose responsiveness, a cell structure containing the insulin-producing cell, and a pharmaceutical composition. According to the present invention, there is provided a method for producing an insulin-producing cell from a mesenchymal stem cell, including (a) a step of producing a cell structure by incubating a plurality of biocompatible macromolecular blocks and a plurality of mesenchymal stem cells, and (b) a step of culturing one or more of the mesenchymal stem cells before the incubation in the step (a), the mesenchymal stem cell in the incubation in the step (a), or the cell structure produced in the step (a) in a medium containing the GLP-1 receptor agonist, and (c) a step of culturing the cell structure obtained in the step (a) or the step (b) in a medium containing the water-soluble vitamin and the hepatocyte growth factor.
Abstract:
A novel tissue usable for a kidney tissue model is provided. A method for producing a kidney-like tissue includes co-culturing a cell group containing mesenchymal stem cells, vascular endothelial cells, and clonal embryonic kidney cells.
Abstract:
Provided is a prophylactic/therapeutic agent for influenza viral infection that is effective not only before and at an early stage of infection with influenza virus but also at an intermediate or late stage of the infection and is highly safe for human bodies. A prophylactic/therapeutic drug for influenza viral infection comprising, as active ingredients, 5-aminolevulinic acid (5-ALA), a derivative thereof or a salt of the 5-ALA or the derivative, and an iron compound is prepared. This prophylactic/therapeutic agent can be used for ameliorating (preventing) depression in food consumption, water consumption and body weight, for ameliorating (decreasing) increase in ketone body levels in blood that may otherwise cause ketosis, for ameliorating (preventing) depression in ATP levels in blood, or for ameliorating (increasing) a survival rate and depression in a body surface temperature.